Evidence map›Paper›PMID 16480670›Full record

ReviewCurrent urology reports2006

Cell type-specific analyses for identifying prostate cancer biomarkers.

Peter S Nelson, Bruce Montgomery

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current urology reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Peter S NelsonFred Hutchinson Cancer Research Center, Division of Human Biology, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA. pnelson@fhcrc.org
Bruce Montgomery
Fred Hutch Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancers of the prostate contribute substantial morbidity and mortality to the male population. The correlation of prostate cancer incidence with aging suggests that the disease burden associated with prostate carcinoma will increase dramatically over the next several decades. Despite the large number of fatalities directly linked to prostate cancer, most men harboring the disease will die of other causes. This fact poses substantial dilemmas for screening programs designed to diagnose cancers at an early stage, as the optimal approach also would provide guidance as to which cancers could or should be observed, versus those malignancies that require curative therapy, and whether localized treatments are sufficient or if additional systemic interventions are indicated. To address these issues, substantial resources have been focused on the identification of biomarkers capable of specifically and sensitively diagnosing prostate cancers and providing prognostic information. However, the discovery and use of biomarkers must contend with the complexity and heterogeneity of body fluids and tissues. This review describes approaches that use cell type-specific analysis methods to identify cancer-associated features with the potential of distinguishing individuals with cancer of the prostate.

Indexed as

Biomarkers, TumorCytological TechniquesDiagnosis, DifferentialHumansMaleProstatic NeoplasmsSensitivity and SpecificityBiomarkers, Tumor

Identifiers

PMID16480670
OpenAlexW2003938449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.